Nek2 as a novel molecular target for the treatment of breast carcinoma

We investigated the role of Nek2, a member of the serine‐threonine kinase family, in the tumorigenic growth of breast carcinoma. Increased expression of Nek2 was observed in all breast carcinoma cell lines examined (BT20, BT474, Hs578T, MCF7, MDA‐MB‐231, T47D, and ZR‐75‐1) by immunoblotting. By trea...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2009-01, Vol.100 (1), p.111-116
Main Authors: Tsunoda, Nobuyuki, Kokuryo, Toshio, Oda, Koji, Senga, Takeshi, Yokoyama, Yukihiro, Nagino, Masato, Nimura, Yuji, Hamaguchi, Michinari
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Breast Neoplasms - chemistry
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cell Line, Tumor
Female
Gynecology. Andrology. Obstetrics
Humans
Male
Mammary gland diseases
Medical sciences
Mice
NIMA-Related Kinases
Original
Protein-Serine-Threonine Kinases - antagonists & inhibitors
Protein-Serine-Threonine Kinases - genetics
Protein-Serine-Threonine Kinases - physiology
Receptors, Estrogen - analysis
RNA, Small Interfering - genetics
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the role of Nek2, a member of the serine‐threonine kinase family, in the tumorigenic growth of breast carcinoma. Increased expression of Nek2 was observed in all breast carcinoma cell lines examined (BT20, BT474, Hs578T, MCF7, MDA‐MB‐231, T47D, and ZR‐75‐1) by immunoblotting. By treatment with Nek2 short interfering RNA (siRNA), expression of Nek2 was clearly decreased in both estrogen receptor (ER)‐positive (MCF7) and ER‐negative (MDA‐MB‐231) breast carcinoma cell lines. Cell growth, colony formation in soft agar, and in vitro invasiveness of these cell lines were substantially suppressed by Nek2 siRNA treatment. In a xenograft nude mouse model with subcutaneous implantation of MCF7 or MDA‐MB‐231, subcutaneous injection of Nek2 siRNA around the tumor nodules resulted in a reduction of tumor size compared with those of control siRNA injection. Taken together, Nek2 appears to play a pivotal role in tumorigenic growth of breast carcinoma cells, and could be a useful therapeutic molecular target for the treatment of breast carcinoma both in ER‐positive and ER‐negative cases. (Cancer Sci 2009; 100: 111–116)
ISSN:1347-9032
1349-7006
1349-7006
DOI:10.1111/j.1349-7006.2008.01007.x